All In Biotech

Drug Trial Radar · NCT07521046

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Aug 2029

Study completion Aug 2030

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
PharmaEssentia
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Conditions

  • Myelofibrosis

Interventions

  • ropeginterferon alfa- 2bDrug

    Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.

  • RuxolitinibDrug

    Ruxolitinib will be administered per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by typeTime frame: 2 years
  2. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).Time frame: 2 years
  3. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.Time frame: 2 years
  4. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.Time frame: 2 years
  5. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huntsman Cancer Institute at University of Utah

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.